-+ 0.00%
-+ 0.00%
-+ 0.00%

HUTCHMED ANNOUNCES NMPA APPROVAL FOR ATLED® (FANREGRATINIB) FOR THE TREATMENT OF PATIENTS WITH FGFR2-FUSION/REARRANGEMENT INTRAHEPATIC CHOLANGIOCARCINOMA

Reuters·08/28/2026 00:00:00

Please log in to view news